Indication
Pneumococcal Infection
6 clinical trials
13 products
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal DiseaseStatus: Completed, Estimated PCD: 2024-02-16
Product
PCV15Product
PPSV23Product
V116Product
Placebo for PCV15 + PPSV23Product
V110Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.Status: Completed, Estimated PCD: 2023-02-21
Product
mRNA-1273Product
PlaceboProduct
V114Clinical trial
A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.Status: Completed, Estimated PCD: 2021-04-06
Product
PNEUMOVAX™23Product
Placebo for V110Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal DiseaseStatus: Recruiting, Estimated PCD: 2025-02-12
Product
PCV20Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve AdultsStatus: Completed, Estimated PCD: 2023-05-18
Clinical trial
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan InfantsStatus: Active (not recruiting), Estimated PCD: 2022-09-30
Product
PCV10Product
PCV13